Differentiating Inflammatory Arthritis from Non-Inflammatory Arthritis in Patients with Knee Mono Arthritis Using IL-17
[1]
Batool Zamani, Kashan University of Medical Science, Faculty of Medicine, Department of Internal Medicine, Rheumatology Ward, Beheshti Hospital Kashan, Iran.
[2]
Maryam Tavassoli, Rheumatology Lab, Beheshti Hospital, Kashan, Iran.
[3]
Fatameh Atoof, Kashan University of Medical Science, Faculty of Medicine, Department of Epidemiology and Statistics, Kashan, Iran.
[4]
Hamidreza Masror, McGill University, Faculty of Medicine, Department of Experimental Surgery, Montreal, QC, Canada.
Objective: Arthritis is one of the most common diseases in patients who have joint problems. Based on a patient’s WBC and polymorphonuclears count, it is divided into inflammatory and non-inflammatory types. IL-17 is an important cytokine causing inflammation in synovia. The objective of this research is to measure the level of IL-17 in joint fluid in order to differentiate inflammatory from non-inflammatory arthritis. Methods: In this case-control study, 40 cases were chosen: 20 patients who have inflammatory knee mono arthritis and 20 with non-inflammatory knee mono arthritis. Their demographic information including age, sex, and duration of disease was recorded by the questioners. After the patients’ consent was obtained, we sent their joint fluid samples to the lab to measure their levels of IL-17. Arthritis was considered inflammatory if there was more than 2000 WBC in one milliliter of joint fluid and non-inflammatory if there was less than 2000. We measured IL-17 using ELISA with KOMA BIOTECH kits. We analyzed the data using SPSS software. Results: In this study we had 18 males (45% of cases) and 22 females (55% of cases).The mean age and the duration of disease were 48+_15.96 Y and 8+_4.8 W respectively. Women had 40.9% inflammatory arthritis and 59.1% non-inflammatory arthritis. Men had 61.1% inflammatory and 38.9% non-inflammatory arthritis. No significant statistical difference was observed between the two groups (P-value=0.2). The means of age in patients who had inflammatory and non-inflammatory arthritis were 38.45+_13.44 and 57.55+_12.24 respectively which had a significant statistical difference (P-value<0.001). The means of disease duration in inflammatory and non-inflammatory arthritis were 5.84+_8.95 and 7.1+_3.24 W respectively (P-value=0.23). The means of the level of IL-17 in cases of inflammatory and non-inflammatory arthritis were 16.04+_5.74 and 8.83+_1.86pg/ml respectively which also had a significant statistical difference (P-value<0.001). To find a cut-off-point for IL-17 to differentiate the diagnosis of inflammatory from non-inflammatory arthritis we used an ROC diagram. The level of 10.5pg/ml of IL-17 is the cut-off-point to differentiate inflammatory from non-inflammatory knee mono arthritis. At this cut-off-point specificity, sensitivity, positive predictive value, and negative predictive value were 0.95, 0.90, 0.90, and 0.95 respectively. Conclusion: This study showed that by measuring the level of IL-17 in a patient, we can differentiate inflammatory from non-inflammatory arthritis.
Inflammatory Arthritis, Non-Inflammatory Arthritis, Interleukin 17
[1]
Bellamy N. Musculoskeletal condition Knee pain. Population Research & Outcom studies unit- south Australialian Department of Health.Epidemologic series report; 2007.
[2]
Milkus TA. Synovial fluid analysis.In: Koopman WJ. Moreland LW. Arthritis& Allied condition. A text book of Rheumatology. Fifteen Ed. 2005: 81-95.
[3]
Shemerling R. Synovial fluid analysis. A critical reeppraisal .Rheuma Dis Clin North Am 1994; 20:503-512.
[4]
Shemerling R, Delbanco T, Tosteson A. Synovial fluid tests. Wath should be ordered? JAMA 1990; 264:1009-1014.
[5]
Kersey R, Benjamine J, Marson B. White blood cell counts and differential in Synovial fluid. J Arthroplasty 2002; 15:301-304.
[6]
Hasselbacher P. Variation in synovial fluid analysis by hospital laboratories. Arthritis Rheuma 1987; 30:637-642.
[7]
Swan A, Amer H, Dieppe P. The value of synovial fluid assay in the diagnosis of joint disease: aliterature survey, Ann Rheum Dis: 2002; 61; 493-98.
[8]
Arend WP: The pathophysiology and treatment of rheumatoid arthritis. Arthritis Rheum 1997, 40:595–597.
[9]
Chizzolini C, Chicheportiche R, Burger D, Dayer JM: Human Th1 cells preferentially induce interleukin (IL)-1beta while Th2 cells induce IL-1 receptor antagonist production upon cell/Cell contact with monocytes. Eur J Immunol 1997, 27:171–177.
[10]
Chomarat P, Rissoan MC, Pin JJ, Banchereau J, Miossec P: Contribution of IL-1, CD 14, CD 13 in the increased IL-6 production during monocyte synoviocyte interactions. J Immunol 1995, 155:3645–3652.
[11]
Manolagas SC. Role of cytokines in bone resorption. Bone 1995, 17:63S–67S.
[12]
Lader CS, Flanagan AM: Prostaglandin E2, interleukin-1a, and tumor necrosis factor- α, increase human osteoblast formation and bone resorption in vitro. Endocrinology 1998, 139:3157–3164.
[13]
Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ,Gillespie MT: Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999, 265:144–150.
[14]
Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, et al. Human IL-17: a novel cytokine derived from T cells.J Immunol 1995; 155:5483–6.
[15]
Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S,Maat C, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996; 183:2593–603.
[16]
Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 2002; 71:1.
[17]
Hymowitz s.g., filvaroff E. H., Yin J.P.,Lee J., Cai L., Risser p.IL-17s adopt a cysteine knot fold: structure and activity of a novel cytokine, IL-17F and implications for receptor binding.EMBO J. 2001;20:5332-5341
[18]
Li H., Chen J.,Huang A., Stinson J., Heldens S., Foster J.Cloning and characterization of IL-17B and IL-17C,two new members of the IL-17 cytokine family. proc. Natl.Acad. sci. USA 2000;97: 773-778
[19]
Shi Y., Ullrich S. J., Connolly k., Grzegorzewski K.J., Barber M. C.a Novel cytokine receptor-ligand pair. Identification, molecular characterization and in vivo immonomodulatory activity. J. Biol. chem. 2000; 275:19167-19176
[20]
Lee J., HO W H., Maruoka M., Corpuz R. T., Baldwin D. T., Foster J. S. IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J. Biol. chem. 2001;276:1660-1664
[21]
Starnes T., Broxmeyer H. E., Robertson M. J. and Hromas R.(2002) IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J. Immunal. 2002; 169:642-646
[22]
Starnes T.,Robertson M. J., Sledge G., KELICH S., Nakshatri H., Broxmeyer H. E. IL-17F, a novel cytokine selectively expressed in activated Tcells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J.Immunal. 2001; 167:4137-4140
[23]
Fosseiz F , Djossou O, Chomarat P, Flores-Romo L, Ait-yahia S,Maat C, pin jj, garrone P, Garcina E, Saeland S, Blanchard D, Gaillard C, Das Mahapatra B, Rouvier E, Golstein P, Banchereau J,lebecque S:T cell IL-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. j Exp med 1996;183:2593-2603.
[24]
Hitchon CA, Alex p, Erdile LB, Frank MB, Dozmorov I, Tang Y, Wong K, Centola M, and El-Gabalawy HS: A distinct multycytokine profile associated with anti-cyclical citrullinated peptide antibodies in patients with ealy untreated inflammatory arthritis. J Rheumatol 2004; 31:2336-2346
[25]
Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, inoue k, kamatani N, Gillespie MT, Martin Tj, Suda T:IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. j clin invest 1999;103:1345-1352
[26]
Ziolkowska M, koc A, luszczykiewicz G, Ksiezopolska-pietrzak K, Klimczak E, chwalinska-sadowska H, Maslinski W:High levels of IL-17 in rheumatoid arthritis patients:IL-15 triggers in vitro IL-17 production via cyclosporine A-sensitive mechanism. j immunal 2000;164:2832-2838.
[27]
lubberts E., Van Den B. L., Oppers-Walgreen B., Schwarzen-berger p., coene-De Roo c. j., kolls j.k.IL-17 promotes bone erosion in murine collage induced arthritis through loss of the receptor activator of NF-kappaB ligand/osteoprotegrin balance.j. immunal.2003; 170:2655-2662
[28]
Oh JY, Kim Mk, Choi HJ, Kang EJ, Lee HJ, Wee WR, Lee JH. Investigating the Relationship between Serum Interleukin-17 Levels and Systemic Immune-Mediated Disease in Patients with Dry Eye Syndrome. Korean J Ophthalmol. 2011 April; 25(2): 73–76.
[29]
Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Rheum Dis Clin North Am. 2008 Aug; 34(3):515-29.
[30]
Pelletier JP, Pelletier JM, Abramson SB. Osteoarthritis, an Inflammatory Disease Potential Implication for the Selection of New Therapeutic Targets. Arthritis and Rheumatism, 2001(44)6:1237–47.
[31]
Günther KP, Puhl W, Brenner H, Stürmer T. Clinical epidemiology of hip and knee joint arthroses: an overview of the results of the "Ulm Osteoarthrosis Study"Z Rheumatol. 2002 Jun; 61(3):244-9.
[32]
Sowers M. Epidemiology of risk factors for osteoarthritis: systemic factors. Curr Opin Rheumatol. 2001 Sep; 13(5):447-51.
[33]
Dougados M. Clinical feature of osteoarthritis .In: Edward D. Harris, JR, Rolph C. Budd, Gary S. Fibrestein, Mark C. Genovese, Johns. Serjent, Shaun Ruddy, Clement B. Sledge. Editors Kelleys text book of Rheumatology 17th ed. Philadelphia. Pennsylvania 19106.2005 p1514-1525
[34]
Elliott AL, Kraus VB, Luta G, Stabler T, Renner JB, Woodard J, Dragomir AD, Helmick CG, Hochberg MC, Jordan JM. Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project. Arthritis Rheum. 2005 Jan; 52(1):105-11.
[35]
Suurmond J1, Dorjée AL, Boon MR, Knol EF, Huizinga TW, Toes RE, et al. Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther. 2011; 13(5):R150.
[36]
Leipe J1, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 2010 Oct; 62(10):2876-85.
[37]
Kim J1, Kang S, Kim J, Kwon G, Koo S. Elevated levels of T helper 17 cells are associated with disease activity in patients with rheumatoid arthritis. Ann Lab Med. 2013 Jan; 33(1):52-9.
[38]
Sarkar S1, Justa S, Brucks M, Endres J, Fox DA, Zhou X, et al. IL-17A, F, and AF in inflammation: a study in collagen induced arthritis and rheumatoid arthritis. Clin Exp Immunol. 2014 May 12.
[39]
MOan R., McCormick J., Connolly M., Sullivan O., FitzGerald O., et al. (2009) Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-α, Oncostatin M and response to biological therapies. Arthritis Res Ther 11: R113
[40]
M.Abdullah R, A.Khalil M, A.Jassim N: Serum IL17 and IL6 levels in a Sample of Iraqi Patients with Rheumatoid Arthritis, Chemistry and Materials Research.2013: Vol.3 No.8
[41]
Roşu A, Mărgăritescu C, Stepan A, Muşetescu A, Ene M,IL-17 patterns in synovium, serum and synovial fluid from treatment-naïve, early rheumatoid arthritis patients.Rom J Morphol Embryol. 2012; 53(1):73-80
[42]
Gary S. Firestein, MD, Ralph C. Budd, MD, Sherine E Gabriel, MD, MSc, Iain B. McInnes, PhD, FRCP, FRSE and James R O'Dell, MD.Kelley's Textbook of Rheumatology.2013.9TH Edition.Valum
[43]
Rabab MA, Makarim AK, Nizar AJ, Faiq IG. Serum IL17 and IL6 levels in a Sample of Iraqi Patients with Rheumatoid Arthritis: A Case Control Study. Chemistry and Materials Research 2013; 3(8): 41-47.
